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Literature Review
Cardiovascular disease develops 10 to15 years later in
women than in men and is the major cause of death in
women older than 65 years of age. The risk of heart
disease in women however is still underestimated and
many women are not aware of their own risk factors.
In a recent report from the European Heart Survey on
stable angina pectoris it was found that women are
less likely to be referred for functional testing for
ischemia, with a lower rate of diagnostic angiograms
and interventional procedures.1
The under-recognition of heart disease and
differences in clinical presentation in women lead to
less aggressive treatment strategies and a lower
representation of women in clinical trials. In the current
review we summarize the major issues that are
important in the diagnosis and treatment of coronary
heart disease (CHD) in women.
Epidemiology and role of menopause
Women with an acute myocardial infarction (AMI)
are in general older than men, with a higher mortality
and a larger co-morbidity in coronary heart disease
risk factors.2-4  It is assumed that exposure to
endogenous estrogens during the fertile period of life
delays the manifestation of atherosclerotic disease in
women. Before menopause the CHD event rate in
women is low and predominantly attributed to
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smoking.5 Women with early menopause (< 40 years)
have a 2–years lower life-expectancy compared with
women with a normal or late menopause.6 Young
women with endogenous estrogen deficiency have a >
7 fold increase in coronary artery risk.7 Estrogens have
a regulating effect on several metabolic factors, such
as lipids, inflammatory markers and the thrombotic
system. They also promote a direct vasodilatory effect
on the α and β-receptors in the vessel wall.8
Premenopausal women with CHD have lower estrogen
levels than healthy women. After menopause
atherosclerotic plaque composition changes into more
vulnerable lesions with inflammatory factors involved.9
Male/female differences in CHD risk factors
Although women and men share most classic
atherogenic risk factors, the significance and the
relative weighting of these factors are different. At
younger ages (<50 years) smoking is more deleterious
in women than in men, with a greater negative impact
of the total number of cigarettes smoked per day.5,10
Heavy female smokers also have a 2 years earlier onset
of menopause. Central obesity with an increase in
visceral fat occurs more frequently after menopause,
with a higher presence of co-morbid risk factors and
components of the metabolic syndrome in women
compared with men11. Women diagnosed with the
polycystic ovary syndrome are at increased risk of the
metabolic syndrome and of type 2 diabetes mellitus.12
Women with diabetes are at greater risk for
cardiovascular complications than their male
counterparts. In a recent meta-analysis of 37
prospective cohort studies, the risk of fatal CHD is
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50% higher in women compared with men.13 The
reason for this higher mortality is multifactorial and
related to a heavier risk factor burden, more
involvement of inflammatory factors, a smaller vessel
size of the coronary arteries and often a less aggressive
treatment of diabetes.14 At older age (> 75 years)
isolated systolic hypertension is 14% more prevalent
in women and an important cause of left ventricular
hypertrophy and (diastolic) heart failure. Moderate or
borderline hypertension (< 140/90 mmHg) causes
more cardiovascular complications and endothelial
dysfunction in women than in men15. Hypertension
often starts in the menopausal transition period and
can cause a variety of complaints, such as chest pain,
palpitations, headaches and even sensations of hot
flashes. Women with a history of hypertensive diseases
in pregnancy are at increased risk for hypertension and
premature cardiovascular disease.16,17
The relative risk of hypercholesterolemia is lower
in women below 65 years of age compared with men.
In the menopause transition total cholesterol levels
rise 10%, low-density lipoprotein (LDL) cholesterol
rises 14% and lipoprotein (a) increases 4 to 8%,
whereas high-density lipoprotein (HDL) cholesterol
levels remain unchanged.18 Therefore it may be
important to (re)evaluate the lipid profile after
menopause. The efficacy of statin therapy in women
has been disputed, but seems similar in risk reduction
in both gender.19
Recently, an update on the guidelines for CHD
risk reduction has been published that underscores the
importance of lifestyle measurements in primary
prevention in women.20 More than 80% of all cases
of CHD in women can be prevented through a healthy
life-style.21
Clinical presentation and non-invasive testing
for angina pectoris
The clinical presentation of coronary heart disease and
non-invasive diagnostic testing is less reliable in women
compared with men, especially in the age-group below
55 years when the prevalence of coronary artery disease
is still relatively low. 22,23
There are no gender-specific criteria for the
interpretation of ECG’s, although women have a
higher heart-rate at rest with a longer QT-interval.
Non-specific ECG changes at rest, a lower exercise
capacity and a smaller vessel size contribute to the lower
sensitivity and specificity of non-invasive testing in
women.  At younger ages, endogenous estrogen levels
can induce ECG-changes. Female-specific normo-
grams have been developed for treadmill exercise
testing.24 A low exercise capacity in symptomatic as
well as in asymptomatic women is a strong predictor
of 5-years mortality. Stress echocardiography with
exercise or dobutamine can be an important test to
predict the presence of CHD and its clinical value is
not different within both gender.
The accuracy of myocardial perfusion imaging scans
used to be less in women due to smaller vessel size and
over-projection of the breasts, but with more advanced
SPECT imaging techniques with Technetium sestimibi
the predictive value of the scans have improved
dramatically.25 Calcium scoring with EBTC or multi-
slice CT is a rapid developing modality to predict the
presence of atherosclerotic disease. The amount of
calcium found in the coronary arteries is a strong
predictor of plaque burden. In women at intermediate
risk for CHD the absence of coronary calcium has a
very high negative predictive value (99%) of coronary
artery disease.26 In all age groups calcium scores are lower
in women than in men.27
Acute coronary syndromes in women
In acute coronary syndromes (ACS), both men and
women have similar symptoms of chest pain, but
women tend to have more concomitant vaso-vegetative
symptoms with less extensive ST-T elevations at
admission, especially at younger ages.3 Women under
55 years are therefore often misdiagnosed at the
emergency department 28. In general, women with ACS
are older with more clustering of risk factors that
contribute to their higher risk in mortality.3,4,29,30
Gender bias in treatment and gender disparities in
vascular flow and structure may further add to this
increased mortality.31,32 Other aspects that may account
for differences in vascular biology between women and
men are related to a smaller vessel size, less collateral
flow, more vascular stiffness, differences in remodeling,
and the function of smooth muscle cells in the vessel
wall. An interesting observation is that women with
ACS have less obstructive coronary artery disease
compared with men, but the event rate in non-
obstructive coronary artery disease seems to be higher
in women.33 Especially young women have more often
ACS with angiographically normal coronary arteries
than men.3.34 The underlying mechanisms are diverse
(e.g. microvascular dysfunction, disturbances in
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vascular reactivity, low endogenous estrogen levels,
coagulation disorders, abnormal inflammatory
reactions etc. and may have a substantial variability
among individuals.35 The prognosis of these syndromes
is less beneficial than initially thought.36
Gender differences after coronary interventions
and heart failure
Gender differences in mortality after coronary artery
bypass surgery (CABG) is higher in women compared
with men, and this difference is more pronounced in
the younger age groups.37,38 Many factors influence
this gender gap, such as co-morbid conditions at older
age, smaller vessel size, more urgent procedures in
women and hypertensive heart disease. Furthermore,
women have significantly more bleeding complications
after percutaneous coronary interventions (PCI).39
Heart failure due to ischemic heart disease is more
prevalent in men, while diastolic heart failure with a
preserved ejection fraction occurs more often in
women.40 At older age, women have more left
ventricular hypertrophy due to hypertension than men.
The lack of estrogen in postmenopausal women may
also contribute to the increase in ventricular mass that
is seen in women at older age.41
Menopausal hormone therapy and CHD risk
Despite the benefits of hormonal therapy (HT) that have
been shown in observational studies, randomized trials
have failed to show any benefit.42 In most observational
studies, however, women started HT for menopausal
symptoms, whereas in experimental studies women
started HT 10 to 20 years after menopause. Initiation of
HT after a recent coronary event results in an early increase
in adverse events.43 Proinflammatory effects of HT on
advanced atherosclerotic lesions are assumed to contribute
to the progression of CHD when present. Data from the
Women’s Health Initiative have shown that HT is not
beneficial in primary prevention either, but it has not
been proven harmful on the vascular system in healthy
women during their early postmenopausal years.44,45
Recent guidelines have been postulated for the use of
HT in the peri-and postmenopause.46 Many determinants
of vasomotor symptoms overlap with CHD risk factors,
such as smoking, obesity, hypertension, lack of exercise
and excessive alcohol use. Life-style measurements are
therefore of primary importance in the treatment of
perimenopausal symptoms.
Conclusion
A greater awareness of the many epidemiological and
biological differences that exist between men and
women may improve our treatment success of CHD
patients in daily practice.
References
1. Daly CA, Clemens F, Sendon JL et al. The clinical
characteristics and investigations planned in patients with
stable angina presenting to cardiologists in Europe: from the
Euro Heart Survey of Stable Angina. Eur Heart J 2005; 26:
996-1010.
2. Wenger NK. Coronary heart disease: an older women’s major
health risk. BMJ 1997; 5:1085-1090.
3. Hochman JS, Tamis, JE, Thompson TD, et al. Sex, clinical
presentation, and outcome in patients with acute coronary
syndromes. N Engl J Med 1999; 341:226-232.
4. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM.
Sex-based differences in early mortality after myocardial
infarction. National Registry of Myocardial Infarction 2
Participants. N Engl J Med 1999; 341:217-225.
5. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J.
Smoking and risk of myocardial infarction in women and
men: longitudinal population study. BMJ 1998; 316:1043-
1047.
6. Ossewaarde ME, Bots ML, Verbeek AL et al. Age at menopause,
cause-specific mortality and total life expectancy. Epidemiology
2005; 16:556-62.
7. Bairey Merz CN, Johnson BD, Sharaf BL et al. Hypoestrogenemia
of hypothalamic origin and coronary artery disease in
premenopausal women: a report from the NHLBI-sponsored
WISE study. J Am Coll Cardiol 2003; 41:413-419.
8. Mendelsohn ME, Karas RH.The protective effects of
estrogen on the cardiovascular system. N Engl J Med
1999;340:1801-1811.
9. Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause
on plaque morphologic characteristics in coronary atherosclerosis.
Am Heart J 2001; 141:S58-62.
10. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids,
blood pressure, and sex differences in myocardial infarction. A
12-year follow-up of the Finnmark Study. Circulation 1996;
93:450-456.
11. Kip KE, Marroquin OC, Kelley DE et al. Clinical importance
of obesity versus the metabolic syndrome in cardiovascular risk
in women. Circulation 2004; 109:706-713.
12. Setji TL, Brown AJ. Polycystic ovary syndrome: diagnosis and
treatment. Am J Med 2007; 120:128-132.
Angela H.E.M.Maas et al: Women Make the Difference in Heart Disease
227Jurnal Kardiologi Indonesia • Vol. 28, No. 3 • Mei 2007
13. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary
heart disease associated with diabetes in men and women: meta-
analysis of 37 prospective cohort studies. BMJ 2006;332:73-78.
14. Nataranjan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex
differences in risk for coronary heart disease mortality associated
with diabetes and established coronary heart disease. Arch Intern
Med 2003;163:1735-1740.
15. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal
blood pressure on the risk of cardiovascular disease. N Engl J
Med 2001; 345:1291-1297.
16. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA.
Cardiovascular health after maternal placental syndromes
(CHAMPS): population-based retrospective cohort study.
Lancet 2005; 366:1787-1803.
17. Smith GC, Pell JP, Walsh D. Pregnancy complications and
maternal risk of ischemic heart  disease: a retrospective cohort
study of 129290 births. Lancet 2001; 357:2002-2006.
18. Matthews KA, Meilahn EN, Kuller LH, Kelsey SF, Caggiula
AW, Wing RR. Menopause and risk factors for coronary heart
disease. N Engl J Med 1989; 321:641-646.
19. Walsh JM. Drug treatment of hyperlipidemia in women. JAMA
2004: 291:2243-2253.
20. Mosca L, Banka CL, Benjamin EJ et al. Evidence-based
guidelines for cardiovascular disease prevention in women: 2007
update. Circulation. 2007; 115(11):1481-501.
21. Stampfer MB, Hu FB, Manson JE, Rimm EB, Willett
WC.Primary prevention of coronary heart disease in women
through diet and lifestyle. N Engl J Med 2000; 343:16-22.
22. Douglas PS, Ginsburg GS. The evaluation of chest pain in
women. N Engl J Med 1996; 334:1311-1315.
23. Mieres JH, Shaw LJ, Arai A et al. Role of non-invasive testing
in the clinical evaluation of women with suspected coronary
artery disease. Circulation 2005; 111:682-696.
24. Gulati M, Black HR, Shaw LJ et al. The prognostic value of a
normogram for exercise capacity in women. N Engl J Med 2005;
353:468-475.
25. Taillefer R, DePuey EG, Udelson JE et al. Comparative
diagnostic accuracy of TL-201 and Tc-99m sestamibi SPECT
imaging in detecting coronary artery disease in women. J Am
Coll Cardiol 1997; 29:69-77.
26. Haberl R, Becker A, Leber A et al. Correlation of coronary
calcification and angiographically documented stenoses in
patients with suspected coronary artery disease: results of 1764
patients. J Am Coll Cardiol 2001; 37:451-457.
27. Oei HS, Vliegenthart R, Hofman A, Oudkerk M, Witteman
JC. Risk factors for coronary calcification in older subjects. Eur
Heart J 2004; 25:48-55.
28. Pope JH, Aufderheide TP, Ruthazer R et al. Missed Diagnoses
of Acute Cardiac Ischemia in  the Emergency Department. N
Engl J Med 2000; 342:1163-1170.
29. De Luca G, Suryapranata H, Dambrink JH et al. Sex-related
differences in outcome after ST—segment elevation myocardial
infarction treated by primary angioplasty: data from the Zwolle
myocardial infarction study. Am Heart J 2004; 148:852-856.
30. Milcent C, Dormont B, Durand-Zaleski I, Steg PG. Gender
differences in hospital mortality and use of percutaneous
coronary intervention in acute myocardial infarction.
Circulation 2007;115:833-839.
31. Vaccarino V, Rathore SS, Wenger NK et al. Sex and racial
differences in the management of acute myocardial infarction,
1994 through 2002. N Engl J Med 2005; 353:671-682.
32. Anderson RD, Pepine CJ. Gender differences in the treatment
for acute myocardial infarction. Bias or biology? Circulation
2007; 115:823-826.
33. Sharaf BL, Shaw L, Johnson BD et al. Any measurable
coronary artery disease identified in women presenting with
ischemic chest pain is associated with an adverse outcome:
findings from the NIH-NHLBI-sponsored WISE study
angiographic core laboratory. J Am Coll Cardiol 2004;
43:292A (abstract).
34. Patel MR, Chen AY, Peterson ED et al. Prevalence, predictors,
and outcomes of patients with non-ST-segment elevation
myocardial infarction and insignificant coronary artery disease:
results from the Can Rapid risk stratification of unstable angina
patients Suppress Adverse outcomes with Early implemantation
of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart
J 2006; 152:641-647.
35. Klein LW. Acute coronary syndromes in young patients with
angiographically normal coronary arteries. Am Heart J
2006;152:607-610.
36. Johnson BD, Shaw LJ, Buchtal et al. Prognosis in women with
myocardial ischemia in the    abscence of obstructive coronary
artery disease: results from the NIH-NHLBI- sponsored
Women’s Ischemia Syndrome Evaluation (WISE). Circulation
2004; 109:2993-2999.
37. Vaccarino V, Abramson JL, Veledar E, et al. Sex differences in
hospital mortality after coronary artery bypass surgery: evidence
for a higher mortality in younger women.
       Circulation 2002; 105:1176-1181.
38. Jacobs AK. Coronary revascularization in women in 2003. Sex
revisited. Circulation 2003; 107:375-377.
39. Alexander KP, Chen AY, Newby LK et al. Sex differences in
major bleeding with  glycoprotein IIb/IIIa inhibitors: results
from the CRUSADE initiative. Circulation 2006;114:1380-
1387
40. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with
preserved ejection fraction in a population-based study. N Engl
J Med 2006; 355:260-269.
41. Hayward CS, Webb CM, Collins P. Effect of sex hormones on
cardiac mass. Lancet 2001; 357:1354-1356.
Jurnal Kardiologi Indonesia
Jurnal Kardiologi Indonesia • Vol. 28, No. 3 • Mei 2007228
42. Maas AH, van der Schouw YT, Grobbee DE, van der Graaf
Y. “Rise and fall”of hormone therapy in postmenopausal
women with cardiovascular disease. Menopause 2004;
11:228-235.
43. Alexander KP, Newby LK, Hellkamp AS, et al. Initiation of
hormone replacement therapy after acute myocardial infarction
is associated with more cardiac events during follow-up. J Am
Coll Cardiol 2001; 38:1-7.
44. The Women’s Health Initiative Steering Committee. Effects of
conjugated equine estrogens in post-menopausal women with
hysterectomy-The WHI randomized controlled trial. JAMA
2004; 291:1701-1712.
45. Clarkson TB. Estrogen effects on arteries vary with stage of
reproductive life and extent of subclinical atherosclerosis
progression. Menopause 2007; 14:373-384.
46. Position Statement of the North American menopause
Society (NAMS). Estrogen and progestogen use in peri-and
postmenopausal women. Menopause 2007; 14:1-7.
